Molgramostim
Molgramostim is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
617 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 21 | 49 | 11 | 2 | 2 | 78 |
| Melanoma | D008545 | — | — | 25 | 44 | 7 | 1 | 6 | 73 |
| Lymphoma | D008223 | — | C85.9 | 18 | 48 | 5 | 1 | 1 | 68 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 12 | 30 | 5 | 2 | 2 | 46 |
| Myeloid leukemia | D007951 | — | C92 | 9 | 22 | 6 | 1 | — | 36 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 10 | 16 | 5 | 2 | — | 30 |
| Lymphoid leukemia | D007945 | — | C91 | 4 | 13 | 1 | 1 | — | 17 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 3 | 7 | 2 | 1 | — | 11 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 7 | 3 | 1 | — | 10 |
| Hepatitis b | D006509 | — | — | — | 2 | 1 | 1 | 1 | 5 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 22 | 29 | 5 | — | — | 48 |
| Prostatic neoplasms | D011471 | — | C61 | 15 | 31 | 3 | — | — | 44 |
| Multiple myeloma | D009101 | — | C90.0 | 14 | 24 | 3 | — | — | 37 |
| Plasma cell neoplasms | D054219 | — | — | 14 | 22 | 3 | — | — | 35 |
| Myelodysplastic syndromes | D009190 | — | D46 | 13 | 18 | 1 | — | 1 | 30 |
| Preleukemia | D011289 | — | — | 12 | 16 | 1 | — | 1 | 27 |
| Carcinoma | D002277 | — | C80.0 | 12 | 14 | 1 | — | — | 24 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 6 | 17 | 3 | — | — | 24 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 13 | 6 | 2 | — | 4 | 22 |
| Recurrence | D012008 | — | — | 11 | 9 | 3 | — | — | 21 |
Show 44 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 27 | 36 | — | — | 2 | 54 |
| Lung neoplasms | D008175 | — | C34.90 | 10 | 17 | — | — | — | 24 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 11 | 15 | — | — | — | 23 |
| Colorectal neoplasms | D015179 | — | — | 11 | 16 | — | — | — | 20 |
| Syndrome | D013577 | — | — | 8 | 12 | — | — | 1 | 19 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 7 | 10 | — | — | — | 16 |
| Non-small-cell lung carcinoma | D002289 | — | — | 6 | 8 | — | — | — | 12 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 3 | 9 | — | — | — | 11 |
| Fallopian tube neoplasms | D005185 | — | — | 5 | 6 | — | — | — | 10 |
| Glioma | D005910 | EFO_0000520 | — | 6 | 5 | — | — | — | 10 |
Show 130 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancytopenia | D010198 | — | D61.81 | 4 | — | — | — | 3 | 7 |
| Leukopenia | D007970 | EFO_0004233 | D72.819 | 3 | — | — | — | 1 | 4 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 3 | — | — | — | — | 3 |
| Kaposi sarcoma | D012514 | — | C46 | 2 | — | — | — | — | 2 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 2 | — | — | — | — | 2 |
| Diffuse intrinsic pontine glioma | D000080443 | — | — | 2 | — | — | — | — | 2 |
| Virus diseases | D014777 | — | B34 | 2 | — | — | — | — | 2 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | 1 | 2 |
| Plasma cell leukemia | D007952 | — | C90.1 | 1 | — | — | — | — | 1 |
| Basal cell carcinoma | D002280 | — | — | 1 | — | — | — | — | 1 |
Show 36 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bone marrow failure disorders | D000080983 | — | — | — | — | — | — | 1 | 1 |
| Herpes simplex | D006561 | — | B00 | — | — | — | — | 1 | 1 |
| Peritonitis | D010538 | EFO_0008588 | K65 | — | — | — | — | 1 | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | — | 1 | 1 |
| Diabetic foot | D017719 | EFO_1001459 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Molgramostim |
| INN | molgramostim |
| Description | Molgramostim is a recombinant granulocyte macrophage colony-stimulating factor which functions as an immunostimulator.
|
| Classification | Protein |
| Drug class | colony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF); colony-stimulating factors: macrophage colony-stimulating factors (M-CSF) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109134 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | B321AL142J (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 402 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use